Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097071 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 299
- Enrollment target
NCT00097071 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 299 participants.
The verdict
NCT00097071, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 299 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications secondary to Type 1 Diabetes. Insulin Aspart (NovoLog®) is an ideal insulin to use in an intensive insulin regimen using continuous subcutaneous insulin injection (CSII) therapy in the pediatric and adolescent age population. This trial compares the safety and efficacy of Insulin Aspart (NovoLog®) and Insulin Lispro (Humalog®) delivered by CSII in children and adolescents with type 1 diabetes.
Interventions
- DRUG insulin aspart
- DRUG insulin lispro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097071
The ClinicalTrials.gov registry entry for NCT00097071 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin aspart is the first listed.
NCT00097071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097071 about?
NCT00097071 is a clinical study titled "Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents". This trial is conducted in the United States of America (USA). It is demonstrated that intensive insulin therapy resulting in good glycaemic control can reduce or delay the incidence of complications secondary to Type 1 Diabetes. Insulin Aspart (NovoLog®) is an ideal insulin to use in an intensive i...
What is the current status of trial NCT00097071?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 299 participants. The study started on 2004-10. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00097071?
The interventions under investigation include: insulin aspart (DRUG), insulin lispro (DRUG).
Who is sponsoring clinical trial NCT00097071?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.